Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine development for hepatitis C.

M Lechmann1, T J Liang

  • 1Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-1800, USA.

Seminars in Liver Disease
|August 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laparoscopic preperitoneal repair for primary falciform ligament herniation.

Annals of the Royal College of Surgeons of England·2020
Same author

Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.

Alimentary pharmacology & therapeutics·2017
Same author

Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Alimentary pharmacology & therapeutics·2016
Same author

Inguinal Hernia: Recurrences, Tailored Surgery & Pubic Inguinal Pain Syndrome (Sportsman Hernia).

Hernia : the journal of hernias and abdominal wall surgery·2015
Same author

Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.

Genes and immunity·2015
Same author

Thymic stromal lymphopoietin deficiency attenuates experimental autoimmune encephalomyelitis.

Clinical and experimental immunology·2015
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Developing an effective hepatitis C virus (HCV) vaccine faces challenges due to viral mutation and immune evasion. Research explores novel vaccine strategies targeting viral heterogeneity and immune responses to prevent chronic infection.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis C virus (HCV) poses a significant global health burden.
  • HCV's rapid mutation and immune evasion mechanisms present major obstacles to vaccine development.

Purpose of the Study:

  • To review the challenges and promising strategies for developing an effective hepatitis C virus (HCV) vaccine.
  • To highlight the importance of targeting viral heterogeneity and inducing robust immune responses.

Main Methods:

  • Review of current scientific literature on HCV vaccine research.
  • Analysis of viral characteristics, host immune responses, and novel vaccine platforms.

Main Results:

  • HCV exhibits high genetic diversity, particularly in its envelope glycoprotein 2, complicating neutralization.

Related Experiment Videos

  • Persistent infection occurs despite immune responses, and efficient culture systems are lacking.
  • Multispecific cellular immunity and cross-reactive antibodies are crucial for infection resolution.

    • Conclusions:

    • An effective HCV vaccine likely requires multiple components to induce both humoral and cellular immunity.
    • Preventing chronic infection, rather than achieving sterilizing immunity, is a key goal for HCV vaccine development.